People
Retro Biosciences announced on Twitter that it is launching with $180 million in funding. Not much is known about the company, except that it indicates it is focused on the “cellular drives of aging.”
Galen Robotics will further benefit from Robert Langer’s extensive experience in biotech startups and hands-on laboratory work.
Noted Harvard researcher Doug Melton is heading to Vertex Pharmaceuticals to head up investigations into potential transformative treatments for type 1 diabetes.
Athira Pharma is circling the wagons and urging shareholders to reject investor Richard Kayne’s calls for a management change.
With the close of these two funds, Andrew Schwab, managing partner at 5AM Ventures, said the firm has raised more than $2.2 billion to invest in the life sciences industry.
Norman E. “Ned” Sharpless will step down from his role as director of the National Cancer Institute (NCI) at the end of this month, after serving in the role since 2017.
David Sabatini’s resignation follows a decision from three senior MIT officers that recommended his tenure’s revocation.
As Novartis explores the possible sell-off of its Sandoz business, the company is undergoing a significant transformation that it says will save about $1 billion in operations costs by 2024.
On March 31, Cambridge, Massachusetts-based Nuvalent announced that Anna Protopapas has been appointed as Chair of its Board of Directors.
Ishtiaq Ali Saaem is sentenced to three years of probation following a guilty plea to charges he obstructed a federal investigation into his efforts to acquire the deadly toxin ricin.
PRESS RELEASES